SightGlass Vision has received a Gold Stevie Award for Technology Breakthrough of the Year for its DOT spectacle lenses, marking a significant milestone for the company’s contrast‑management approach to slowing myopia progression in children. Presented in the Healthcare Technology category at the 2026 Stevie Awards for Technology Excellence, judges described the technology as a “standout healthcare innovation.”
Quick Take
SightGlass Vision has been awarded the Gold Stevie Award for Technology Breakthrough of the Year for its Diffusion Optics Technology (DOT) spectacle lenses. The award recognizes the company's unique contrast-management approach, which is specifically designed to slow the progression of myopia in children.
Why It Matters
The recognition of DOT lenses at the 2026 Stevie Awards for Technology Excellence highlights a significant shift toward non-invasive, spectacle-based myopia management. Unlike traditional methods that rely on peripheral defocus, SightGlass Vision’s technology focuses on modulating contrast, offering a distinct mechanism of action for clinicians to consider. As myopia rates continue to climb globally, such high-profile technological validation may increase parent and practitioner confidence in adopting advanced spectacle designs over standard single-vision lenses.
Key Details
Who's Affected
What's Next
Following this technological recognition, the industry will likely watch for expanded clinical data and broader commercial availability. Practitioners should stay informed on how contrast-management technology compares to existing peripheral defocus options as they refine their myopia management protocols.
AI-generated summary — always read the original source for full context
No comments yet. Be the first to share your thoughts.
